Research on the identification of immune cell subtypes in the new ovarian cancer tumor microenvironment based on full-spectrum flow cytometry and its application in individualized precision therapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036898

Enrollment

Unknown

Registered

2020-08-25

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

A:Paclitaxel plus carboplatin

B:PD-1 blocker (Pembrolizumab)

Eligibility

Sex/Gender

Female

Age

20 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Ascites in patients with advanced primary or recurrent ovarian cancer; 2. Have not received immune-related treatment in the past; 3. Aged >=20 years old; 4. Good function of multiple organs; 5. Able to follow the research protocol and follow up on schedule; 6. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who have used immunotherapy in the past or are receiving immunotherapy; 2. There are uncontrollable serious diseases such as active tuberculosis, hepatitis B\C and HIV infection; 3. Complicated with other malignant tumors that require intervention; 4. Complicated with other underlying diseases that require immunotherapy; 5. Those who cannot follow the research plan; 6. Other conditions (religion, psychology, etc.) affect informed consent, compliance with the research protocol, or failure to follow up on schedule.

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Secondary

Measure	Time frame
Progression-free survival;	—

Countries

China

Contacts

Public ContactWang ziliang

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

wangziliang@xinhuamed.com.cn+86 13918584458

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026